Arrowhead Pharmaceuticals Inc Market Cap ($8.35 Billion)
Market Cap & Net Worth: Arrowhead Pharmaceuticals Inc (ARWR)
Arrowhead Pharmaceuticals Inc market cap. Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) has a market capitalization of $8.35 Billion ($8.35 Billion) as of November 1, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #2455 globally and #913 in its home market, demonstrating a 2.64% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Arrowhead Pharmaceuticals Inc's stock price $59.90 by its total outstanding shares 139408632 (139.41 Million). Also see ARWR cash flow conversion for how efficiently the company converts equity into cash flow.
Arrowhead Pharmaceuticals Inc Market Cap History (2015–2026)
Arrowhead Pharmaceuticals Inc market cap history from 2015 to 2026. Data shows growth from $857.36 Million to $8.35 Billion (24.68% CAGR). Check ARWR stock price for real-time trading data and today's change.
Index Memberships
Arrowhead Pharmaceuticals Inc is a constituent of 4 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.32% | #58 of 976 |
|
NASDAQ Composite
IXIC
|
$40.09 Trillion | 0.02% | #286 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.84 Trillion | 0.45% | #40 of 263 |
|
S&P Small-Cap 600 Index
SML
|
$1.56 Trillion | 0.12% | #16 of 602 |
Weight: Arrowhead Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Arrowhead Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Arrowhead Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset momentum of Arrowhead Pharmaceuticals Inc to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
11.16x
Arrowhead Pharmaceuticals Inc's market cap is 11.16 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $216.08 Million | $158.33K | -$81.72 Million | 1364.74x | N/A |
| 2017 | $513.02 Million | $31.41 Million | -$34.38 Million | 16.33x | N/A |
| 2018 | $1.73 Billion | $16.14 Million | -$54.45 Million | 107.26x | N/A |
| 2019 | $8.84 Billion | $168.80 Million | $67.97 Million | 52.39x | 130.09x |
| 2020 | $10.70 Billion | $87.99 Million | -$84.55 Million | 121.57x | N/A |
| 2021 | $9.24 Billion | $138.29 Million | -$140.85 Million | 66.84x | N/A |
| 2022 | $5.65 Billion | $243.23 Million | -$176.49 Million | 23.25x | N/A |
| 2023 | $4.27 Billion | $240.74 Million | -$205.28 Million | 17.72x | N/A |
| 2024 | $2.62 Billion | $3.55 Million | -$599.49 Million | 738.07x | N/A |
| 2025 | $9.26 Billion | $829.45 Million | -$1.63 Million | 11.16x | N/A |
Competitor Companies of ARWR by Market Capitalization
Companies near Arrowhead Pharmaceuticals Inc in the global market cap rankings as of November 1, 2026. Also see ARWR total asset value for a full breakdown of the balance sheet.
Key companies related to Arrowhead Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of Arrowhead Pharmaceuticals Inc (2015–2026)
Market capitalization of Arrowhead Pharmaceuticals Inc from 2015 to today. Between 2015 and today, Arrowhead Pharmaceuticals Inc's market cap moved from $857.36 Million to $ 8.35 Billion, with a yearly change of 24.68%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $8.35 Billion | -9.78% |
| 2025 | $9.26 Billion | +253.14% |
| 2024 | $2.62 Billion | -38.56% |
| 2023 | $4.27 Billion | -24.56% |
| 2022 | $5.65 Billion | -38.82% |
| 2021 | $9.24 Billion | -13.59% |
| 2020 | $10.70 Billion | +20.97% |
| 2019 | $8.84 Billion | +410.71% |
| 2018 | $1.73 Billion | +237.50% |
| 2017 | $513.02 Million | +137.42% |
| 2016 | $216.08 Million | -74.80% |
| 2015 | $857.36 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Arrowhead Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $8.35 Billion USD |
| MoneyControl | $8.35 Billion USD |
| MarketWatch | $8.35 Billion USD |
| marketcap.company | $8.35 Billion USD |
| Reuters | $8.35 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Arrowhead Pharmaceuticals Inc
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, a… Read more